NO310196B1 - Proteinkinase C-inhibitor, anvendelse av samme for fremstilling av medikament, farmasöytisk formulering omfattendesamme, fremgangsmåte for fremstilling av samme, samt forbindelsefor bruk som terapeutikum - Google Patents

Proteinkinase C-inhibitor, anvendelse av samme for fremstilling av medikament, farmasöytisk formulering omfattendesamme, fremgangsmåte for fremstilling av samme, samt forbindelsefor bruk som terapeutikum Download PDF

Info

Publication number: NO310196B1
Authority: NO; Norway
Prior art keywords: salt; compound; same; water; reaction
Prior art date: 1995-11-20

Application number

NO19982182A

Other languages

English (en)

Norwegian (no)

Other versions

NO982182L (no

NO982182D0 (no

Inventor

Gary Lowell Engel

Nagy Alphonse Farid

Margaret Mary Faul

Michael Robert Jirousek

Lori Ann Richardson

Jr Leonard Larry Winneroski

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-20

Filing date

1998-05-13

Publication date

2001-06-05

1998-05-13 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1998-05-13 Publication of NO982182L publication Critical patent/NO982182L/no

1998-05-13 Publication of NO982182D0 publication Critical patent/NO982182D0/no

2001-06-05 Publication of NO310196B1 publication Critical patent/NO310196B1/no

Links

150000001875 compounds Chemical class 0.000 title claims description 57
238000000034 method Methods 0.000 title claims description 12
238000002360 preparation method Methods 0.000 title claims description 10
239000003814 drug Substances 0.000 title claims description 7
239000008194 pharmaceutical composition Substances 0.000 title claims description 7
230000001225 therapeutic effect Effects 0.000 title claims description 5
229940123924 Protein kinase C inhibitor Drugs 0.000 title description 3
229940079593 drug Drugs 0.000 title description 3
239000003881 protein kinase C inhibitor Substances 0.000 title description 3
101710175516 14 kDa zinc-binding protein Proteins 0.000 title description 2
150000003839 salts Chemical class 0.000 claims description 60
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 43
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 40
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
239000000203 mixture Substances 0.000 claims description 27
239000002904 solvent Substances 0.000 claims description 22
238000004519 manufacturing process Methods 0.000 claims description 15
-1 pyrrolo[3,4-H] [ 1,4,13 ]-oxadiazacyclohexadecine-1,3 (2H)-dione methanesulfonate monohydrate Chemical compound 0.000 claims description 14
239000000126 substance Substances 0.000 claims description 13
239000012453 solvate Substances 0.000 claims description 8
238000009472 formulation Methods 0.000 claims description 7
229940098779 methanesulfonic acid Drugs 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 5
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 claims description 3
208000002249 Diabetes Complications Diseases 0.000 claims description 2
206010012655 Diabetic complications Diseases 0.000 claims description 2
239000000969 carrier Substances 0.000 claims description 2
DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims description 2
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 77
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 51
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
238000006243 chemical reaction Methods 0.000 description 33
239000011541 reaction mixture Substances 0.000 description 32
239000000243 solution Substances 0.000 description 32
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
239000012044 organic layer Substances 0.000 description 27
235000019439 ethyl acetate Nutrition 0.000 description 26
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
239000000460 chlorine Substances 0.000 description 24
108090000315 Protein Kinase C Proteins 0.000 description 22
102000003923 Protein Kinase C Human genes 0.000 description 22
239000007787 solid Substances 0.000 description 21
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 19
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
108010044467 Isoenzymes Proteins 0.000 description 17
239000010410 layer Substances 0.000 description 16
238000004128 high performance liquid chromatography Methods 0.000 description 14
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
239000012267 brine Substances 0.000 description 11
150000003840 hydrochlorides Chemical class 0.000 description 11
239000003921 oil Substances 0.000 description 11
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 10
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 8
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
235000019270 ammonium chloride Nutrition 0.000 description 8
238000000746 purification Methods 0.000 description 8
239000000725 suspension Substances 0.000 description 8
239000004480 active ingredient Substances 0.000 description 7
201000010099 disease Diseases 0.000 description 7
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 7
238000010992 reflux Methods 0.000 description 7
239000012047 saturated solution Substances 0.000 description 7
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 6
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 6
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
206010012601 diabetes mellitus Diseases 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
238000002844 melting Methods 0.000 description 6
230000008018 melting Effects 0.000 description 6
239000002207 metabolite Substances 0.000 description 6
150000003013 phosphoric acid derivatives Chemical class 0.000 description 6
230000036470 plasma concentration Effects 0.000 description 6
239000002002 slurry Substances 0.000 description 6
229940095064 tartrate Drugs 0.000 description 6
241000124008 Mammalia Species 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
239000002585 base Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
239000012458 free base Substances 0.000 description 5
239000012535 impurity Substances 0.000 description 5
239000012528 membrane Substances 0.000 description 5
238000000386 microscopy Methods 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
238000000634 powder X-ray diffraction Methods 0.000 description 5
230000009467 reduction Effects 0.000 description 5
239000003826 tablet Substances 0.000 description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
241000282472 Canis lupus familiaris Species 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
238000005481 NMR spectroscopy Methods 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
235000001465 calcium Nutrition 0.000 description 4
239000011575 calcium Substances 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
230000003197 catalytic effect Effects 0.000 description 4
238000001816 cooling Methods 0.000 description 4
238000001035 drying Methods 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
235000021317 phosphate Nutrition 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
208000024172 Cardiovascular disease Diseases 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
102000001253 Protein Kinase Human genes 0.000 description 3
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
238000002441 X-ray diffraction Methods 0.000 description 3
159000000021 acetate salts Chemical class 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
229910000024 caesium carbonate Inorganic materials 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
208000015114 central nervous system disease Diseases 0.000 description 3
150000001982 diacylglycerols Chemical class 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
239000012467 final product Substances 0.000 description 3
FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 3
150000004677 hydrates Chemical class 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
208000028867 ischemia Diseases 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 3
239000002480 mineral oil Substances 0.000 description 3
235000010446 mineral oil Nutrition 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
150000003904 phospholipids Chemical class 0.000 description 3
108060006633 protein kinase Proteins 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
239000011734 sodium Substances 0.000 description 3
239000012312 sodium hydride Substances 0.000 description 3
229910000104 sodium hydride Inorganic materials 0.000 description 3
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
230000004580 weight loss Effects 0.000 description 3
MSICOSWQOQACHW-FQEVSTJZSA-N (2s)-5-trityloxypentan-2-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCCC[C@@H](O)C)C1=CC=CC=C1 MSICOSWQOQACHW-FQEVSTJZSA-N 0.000 description 2
GHCPFMUMJNJKLO-DEOSSOPVSA-N (3s)-3-(2-hydroxyethoxy)-4-trityloxybutan-1-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OC[C@H](CCO)OCCO)C1=CC=CC=C1 GHCPFMUMJNJKLO-DEOSSOPVSA-N 0.000 description 2
XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
239000012359 Methanesulfonyl chloride Substances 0.000 description 2
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
241000276498 Pollachius virens Species 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
BEIIPJGHIJEDMT-SANMLTNESA-N [(3s)-3-(2-methylsulfonyloxyethoxy)-4-trityloxybutyl] methanesulfonate Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OC[C@H](CCOS(C)(=O)=O)OCCOS(=O)(=O)C)C1=CC=CC=C1 BEIIPJGHIJEDMT-SANMLTNESA-N 0.000 description 2
230000004913 activation Effects 0.000 description 2
BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
230000005587 bubbling Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
229910021641 deionized water Inorganic materials 0.000 description 2
238000000113 differential scanning calorimetry Methods 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
238000004817 gas chromatography Methods 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
125000001442 methylidyne group Chemical group [H]C#[*] 0.000 description 2
150000004682 monohydrates Chemical class 0.000 description 2
230000007823 neuropathy Effects 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
230000007170 pathology Effects 0.000 description 2
230000010287 polarization Effects 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
239000002516 radical scavenger Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000012279 sodium borohydride Substances 0.000 description 2
229910000033 sodium borohydride Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
239000008107 starch Substances 0.000 description 2
229910021653 sulphate ion Inorganic materials 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
150000004684 trihydrates Chemical class 0.000 description 2
HVLLSGMXQDNUAL-UHFFFAOYSA-N triphenyl phosphite Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)OC1=CC=CC=C1 HVLLSGMXQDNUAL-UHFFFAOYSA-N 0.000 description 2
JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
238000005303 weighing Methods 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
CTKINSOISVBQLD-GSVOUGTGSA-N (R)-Glycidol Chemical compound OC[C@@H]1CO1 CTKINSOISVBQLD-GSVOUGTGSA-N 0.000 description 1
CTKINSOISVBQLD-VKHMYHEASA-N (S)-Glycidol Chemical compound OC[C@H]1CO1 CTKINSOISVBQLD-VKHMYHEASA-N 0.000 description 1
PYNDRJVXDYBAEV-UHFFFAOYSA-N 1-trityloxypentan-2-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCC(O)CCC)C1=CC=CC=C1 PYNDRJVXDYBAEV-UHFFFAOYSA-N 0.000 description 1
GHCPFMUMJNJKLO-UHFFFAOYSA-N 3-(2-hydroxyethoxy)-4-trityloxybutan-1-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCC(CCO)OCCO)C1=CC=CC=C1 GHCPFMUMJNJKLO-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
241000220479 Acacia Species 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
235000006491 Acacia senegal Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
108010026870 Calcium-Calmodulin-Dependent Protein Kinases Proteins 0.000 description 1
102000019025 Calcium-Calmodulin-Dependent Protein Kinases Human genes 0.000 description 1
102000011632 Caseins Human genes 0.000 description 1
108010076119 Caseins Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
208000036566 Erythroleukaemia Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
239000007832 Na2SO4 Substances 0.000 description 1
101100481019 Nicotiana tabacum TGA1A gene Proteins 0.000 description 1
102000015439 Phospholipases Human genes 0.000 description 1
108010064785 Phospholipases Proteins 0.000 description 1
102000015766 Protein Kinase C beta Human genes 0.000 description 1
108010024526 Protein Kinase C beta Proteins 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
SWAWYMIKGOHZMR-UHFFFAOYSA-N Ro 31-6045 Chemical compound C1=CC=C2C(C=3C(=O)N(C(C=3C=3C4=CC=CC=C4NC=3)=O)C)=CNC2=C1 SWAWYMIKGOHZMR-UHFFFAOYSA-N 0.000 description 1
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
FHNINJWBTRXEBC-UHFFFAOYSA-N Sudan III Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC(C=C1)=CC=C1N=NC1=CC=CC=C1 FHNINJWBTRXEBC-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
101150092207 TGA1 gene Proteins 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
WSPHCJTTZKZGQL-UHFFFAOYSA-N [diphenyl(2-prop-2-enoxypent-4-enoxy)methyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OCC(OCC=C)CC=C)C1=CC=CC=C1 WSPHCJTTZKZGQL-UHFFFAOYSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000011149 active material Substances 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
150000007860 aryl ester derivatives Chemical class 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
150000003924 bisindolylmaleimides Chemical class 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036765 blood level Effects 0.000 description 1
KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
102000043927 cAMP-dependent protein kinase catalytic subunit Human genes 0.000 description 1
108700038308 cAMP-dependent protein kinase catalytic subunit Proteins 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000000378 calcium silicate Substances 0.000 description 1
229910052918 calcium silicate Inorganic materials 0.000 description 1
229960003340 calcium silicate Drugs 0.000 description 1
235000012241 calcium silicate Nutrition 0.000 description 1
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000023549 cell-cell signaling Effects 0.000 description 1
239000007806 chemical reaction intermediate Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
238000010835 comparative analysis Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
238000003869 coulometry Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
229940014259 gelatin Drugs 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
238000000021 kinase assay Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000004526 pharmaceutical effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
150000004633 phorbol derivatives Chemical class 0.000 description 1
239000002644 phorbol ester Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000003880 polar aprotic solvent Substances 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
LZFIOSVZIQOVFW-UHFFFAOYSA-N propyl 2-hydroxybenzoate Chemical class CCCOC(=O)C1=CC=CC=C1O LZFIOSVZIQOVFW-UHFFFAOYSA-N 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
238000010791 quenching Methods 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000009518 sodium iodide Nutrition 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
150000003890 succinate salts Chemical class 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229940099373 sudan iii Drugs 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
JCNIZAUNRMNLSD-IBGZPJMESA-N tert-butyl-[(2s)-4-iodo-2-(2-iodoethoxy)butoxy]-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](OC[C@H](CCI)OCCI)(C(C)(C)C)C1=CC=CC=C1 JCNIZAUNRMNLSD-IBGZPJMESA-N 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
238000002411 thermogravimetry Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
102000009310 vitamin D receptors Human genes 0.000 description 1
108050000156 vitamin D receptors Proteins 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Enzymes And Modification Thereof (AREA)

NO19982182A 1995-11-20 1998-05-13 Proteinkinase C-inhibitor, anvendelse av samme for fremstilling av medikament, farmasöytisk formulering omfattendesamme, fremgangsmåte for fremstilling av samme, samt forbindelsefor bruk som terapeutikum NO310196B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US697095P	1995-11-20	1995-11-20
PCT/US1996/018512 WO1997018809A1 (en)	1995-11-20	1996-11-18	Protein kinase c inhibitor

Publications (3)

Publication Number	Publication Date
NO982182L NO982182L (no)	1998-05-13
NO982182D0 NO982182D0 (no)	1998-05-13
NO310196B1 true NO310196B1 (no)	2001-06-05

Family

ID=21723527

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19982182A NO310196B1 (no)	1995-11-20	1998-05-13	Proteinkinase C-inhibitor, anvendelse av samme for fremstilling av medikament, farmasöytisk formulering omfattendesamme, fremgangsmåte for fremstilling av samme, samt forbindelsefor bruk som terapeutikum

Country Status (34)

Country	Link
US (3)	US5710145A (es)
EP (1)	EP0776895B1 (es)
JP (1)	JP3348859B2 (es)
KR (1)	KR100304210B1 (es)
CN (1)	CN1093759C (es)
AR (2)	AR004336A1 (es)
AT (1)	ATE172199T1 (es)
AU (1)	AU711125B2 (es)
BR (1)	BR9611724A (es)
CA (1)	CA2237221C (es)
CO (1)	CO4750823A1 (es)
CY (1)	CY2103B1 (es)
CZ (1)	CZ297524B6 (es)
DE (1)	DE69600784T2 (es)
DK (1)	DK0776895T3 (es)
EA (1)	EA000967B1 (es)
EG (1)	EG23871A (es)
ES (1)	ES2122764T3 (es)
HU (1)	HU226821B1 (es)
IL (1)	IL124417A (es)
MX (1)	MX9803792A (es)
MY (1)	MY118068A (es)
NO (1)	NO310196B1 (es)
NZ (1)	NZ323571A (es)
PE (1)	PE22798A1 (es)
PL (1)	PL184715B1 (es)
RO (1)	RO120074B1 (es)
SI (1)	SI0776895T1 (es)
TR (1)	TR199800759T2 (es)
TW (1)	TW403754B (es)
UA (1)	UA61897C2 (es)
WO (1)	WO1997018809A1 (es)
YU (1)	YU49315B (es)
ZA (1)	ZA969646B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5624949A (en) *	1993-12-07	1997-04-29	Eli Lilly And Company	Protein kinase C inhibitors
US6093740A (en) *	1997-04-30	2000-07-25	Eli Lilly And Company	Therapeutic treatment for skin disorders
AR017200A1 (es)	1997-12-23	2001-08-22	Astrazeneca Ab	Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
US6620977B1 (en)	1998-01-30	2003-09-16	Daiso Co., Ltd.	Process for producing butanetriol derivative
US6225301B1 (en) *	1998-03-05	2001-05-01	Eli Lilly And Company	Therapeutic treatment for renal dysfunction
US6291446B1 (en)	1998-03-05	2001-09-18	Eli Lilly And Company	Therapeutic treatment for cytomegalovirus infection
US6103713A (en) *	1998-03-05	2000-08-15	Eli Lilly And Company	Therapeutic treatment for autoimmune diseases
US6103712A (en) *	1998-03-05	2000-08-15	Eli Lilly And Company	Therapeutic treatment for asthma
CA2245029A1 (en)	1998-03-13	1999-09-13	University Of British Columbia	Granulatimide compounds as g2 checkpoint inhibitors
SE9800835D0 (sv)	1998-03-13	1998-03-13	Astra Ab	New Compounds
WO1999047522A1 (en) *	1998-03-13	1999-09-23	The University Of British Columbia	Granulatimide derivatives for use in cancer treatment
US6706721B1 (en) *	1998-04-29	2004-03-16	Osi Pharmaceuticals, Inc.	N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US6127401A (en)	1998-06-05	2000-10-03	Cephalon, Inc.	Bridged indenopyrrolocarbazoles
TWI223598B (en) *	1998-06-22	2004-11-11	Pfizer Ireland Pharmaceuticals	An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
GB9828640D0 (en) *	1998-12-23	1999-02-17	Smithkline Beecham Plc	Novel method and compounds
US6841567B1 (en) *	1999-02-12	2005-01-11	Cephalon, Inc.	Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6492406B1 (en)	1999-05-21	2002-12-10	Astrazeneca Ab	Pharmaceutically active compounds
US6284783B1 (en)	1999-06-09	2001-09-04	The Uab Research Foundation	Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
US6399780B1 (en)	1999-08-20	2002-06-04	Cephalon, Inc.	Isomeric fused pyrrolocarbazoles and isoindolones
UA74803C2 (uk)	1999-11-11	2006-02-15	Осі Фармасьютікалз, Інк.	Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) *	1999-11-11	2006-08-08	Osi Pharmaceuticals, Inc.	Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
US6852688B2 (en)	2000-03-10	2005-02-08	University Of Florida	Compositions for treating diabetic retinopathy and methods of using same
AU2001271614B2 (en) *	2000-07-03	2007-05-31	Catalent Pharma Solutions, Llc	Host cells containing multiple integrating vectors
US20030224415A1 (en) *	2001-06-29	2003-12-04	Gala Design, Inc.	Selection free growth of host cells containing multiple integrating vectors
US20020106729A1 (en) *	2000-07-03	2002-08-08	Bleck Gregory T.	Expression vectors
US6300106B1 (en) *	2000-11-22	2001-10-09	Ppg Industries Ohio, Inc.	Method of preparing 3-[2-{(Methylsulfonyl)oxy}-ethoxy ]-4-(triphenylmethoxy)-1-butanol, methane sulfonate
US20040038304A1 (en) *	2002-03-28	2004-02-26	Gala Design, Inc.	Antibody libraries
US7384738B2 (en) *	2002-03-28	2008-06-10	Bremel Robert D	Retrovirus-based genomic screening
CA2484797A1 (en) *	2002-05-06	2003-11-13	Washington University	Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
DE10244453A1 (de) *	2002-09-24	2004-04-01	Phenomiques Gmbh	Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7232842B2 (en) *	2003-01-10	2007-06-19	Board Of Trustees Of The Leland Stanford Junior University	Kinase inhibitors and associated pharmaceutical compositions and methods of use
ES2338789T3 (es)	2003-06-18	2010-05-12	Tranzyme Pharma Inc.	Antagonistas macrociclicos del receptor de motilina.
US20050152942A1 (en) *	2003-12-23	2005-07-14	Medtronic Vascular, Inc.	Medical devices to treat or inhibit restenosis
US20050221429A1 (en) *	2004-01-16	2005-10-06	Cardinal Health Pts, Llc	Host cells containing multiple integrating vectors comprising an amplifiable marker
AU2005221283C1 (en) *	2004-03-17	2011-02-03	Lars Michael Larsen	Prevention of retinopathy by inhibition of the visual cycle
DE102004019413A1 (de) *	2004-04-19	2005-11-24	Phenos Gmbh	Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten
US20090111786A1 (en) *	2004-12-03	2009-04-30	Glass Christopher K	Compounds that Prevent Macrophage Apoptosis and Uses Thereof
US20070281988A1 (en) *	2004-12-20	2007-12-06	Cameron Norman E	Combination Therapy for Vascular Complications Associated with Hyperglycemia
US8034823B2 (en) *	2005-02-22	2011-10-11	Savvipharm Inc	Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
GB0504203D0 (en) *	2005-03-01	2005-04-06	Novartis Ag	Organic compounds
US8158586B2 (en) *	2005-04-11	2012-04-17	Pharmagap Inc.	Inhibitors of protein kinases and uses thereof
WO2008027619A2 (en)	2006-09-01	2008-03-06	Intermec Ip Corp.	Rfid tag system with block coding, such as space-time block coding
PE20091522A1 (es) *	2007-12-21	2009-10-29	Novartis Ag	Composicion farmaceutica solida que contiene 3-(1.h-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4-il]-quinazolin-4-il]-pirrol-2,5-diona
EP2181999A1 (en)	2008-11-03	2010-05-05	Zentiva, A.S.	Method of manufacturing ruboxistarin
US9265764B2 (en) *	2009-02-27	2016-02-23	Massachusetts Institute Of Technology	Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
JP2013523678A (ja)	2010-03-30	2013-06-17	ノバルティスアーゲー	慢性的に活性なｂ細胞受容体シグナル伝達を有するｂ細胞リンパ腫の治療用のｐｋｃ阻害薬
AU2013352379B2 (en)	2012-11-29	2018-09-06	Novartis Ag	Pharmaceutical combinations
WO2014174478A1 (en)	2013-04-26	2014-10-30	Novartis Ag	Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
JO3589B1 (ar)	2014-08-06	2020-07-05	Novartis Ag	مثبطات كيناز البروتين c وطرق استخداماتها
WO2018118874A1 (en)	2016-12-19	2018-06-28	Chromaderm, Inc.	Methods of treating hyperpigmentation disorders
WO2018175340A1 (en)	2017-03-20	2018-09-27	Sienna Biopharmaceuticals, Inc.	Reduced exposure conjugates modulating therapeutic targets
WO2018175302A1 (en)	2017-03-20	2018-09-27	Sienna Biopharmaceuticals, Inc.	Polymer conjugates targeting c-src with reduced exposure
PT3658142T (pt)	2017-07-28	2024-06-27	Applied Therapeutics Inc	Composições e métodos para tratar galactosemia
MX2022013658A (es)	2020-05-01	2023-03-01	Applied Therapeutics Inc	Inhibidores de la aldosa reductasa para tratar la deficiencia de sorbitol deshidrogenasa.
KR20230128175A (ko) *	2022-02-25	2023-09-04	주식회사 온코크로스	루복시스타우린을 포함하는 항암용 조성물
EP4525862A1 (en)	2022-05-20	2025-03-26	Dermbiont, Inc.	Compositions and formulations for use of a pk inhibitor for the prevention, treatment, and improvement of skin diseases, conditions, and disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ280738B6 (cs) *	1988-02-10	1996-04-17	F. Hoffmann - La Roche And Co., Aktiengesellschaft	Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
US5292747A (en) *	1990-08-07	1994-03-08	Hoffman-La Roche Inc.	Substituted pyrroles
AU5100393A (en) *	1992-09-25	1994-04-26	Schering Corporation	Diindolo compounds and pharmaceutical compositions containing them
US5624949A (en) *	1993-12-07	1997-04-29	Eli Lilly And Company	Protein kinase C inhibitors
UA44690C2 (uk)	1993-12-07	2002-03-15	Елі Ліллі Енд Компані	Макроциклічна сполука іміду біс-індол-малеїнової кислоти, спосіб її одержання та фармацевтична композиція, макроциклічні сполуки іміду біс-індол-малеїнової кислоти та біс-індол-малеїнового ангідриду, спосіб одержання (варіанти)

1996
- 1996-11-18 PE PE1996000829A patent/PE22798A1/es not_active Application Discontinuation
- 1996-11-18 AU AU10548/97A patent/AU711125B2/en not_active Ceased
- 1996-11-18 DE DE69600784T patent/DE69600784T2/de not_active Expired - Lifetime
- 1996-11-18 HU HU9903377A patent/HU226821B1/hu not_active IP Right Cessation
- 1996-11-18 UA UA98052515A patent/UA61897C2/uk unknown
- 1996-11-18 CA CA002237221A patent/CA2237221C/en not_active Expired - Fee Related
- 1996-11-18 ZA ZA9609646A patent/ZA969646B/xx unknown
- 1996-11-18 NZ NZ323571A patent/NZ323571A/xx not_active IP Right Cessation
- 1996-11-18 TR TR1998/00759T patent/TR199800759T2/xx unknown
- 1996-11-18 RO RO98-00955A patent/RO120074B1/ro unknown
- 1996-11-18 EA EA199800374A patent/EA000967B1/ru not_active IP Right Cessation
- 1996-11-18 JP JP51983697A patent/JP3348859B2/ja not_active Expired - Fee Related
- 1996-11-18 AT AT96308318T patent/ATE172199T1/de active
- 1996-11-18 CZ CZ0150298A patent/CZ297524B6/cs not_active IP Right Cessation
- 1996-11-18 SI SI9630038T patent/SI0776895T1/xx unknown
- 1996-11-18 WO PCT/US1996/018512 patent/WO1997018809A1/en not_active Ceased
- 1996-11-18 ES ES96308318T patent/ES2122764T3/es not_active Expired - Lifetime
- 1996-11-18 BR BR9611724A patent/BR9611724A/pt not_active Application Discontinuation
- 1996-11-18 IL IL12441796A patent/IL124417A/en not_active IP Right Cessation
- 1996-11-18 TW TW085114103A patent/TW403754B/zh not_active IP Right Cessation
- 1996-11-18 US US08/749,607 patent/US5710145A/en not_active Expired - Lifetime
- 1996-11-18 KR KR1019980703622A patent/KR100304210B1/ko not_active Expired - Fee Related
- 1996-11-18 CN CN96198420A patent/CN1093759C/zh not_active Expired - Lifetime
- 1996-11-18 PL PL96326754A patent/PL184715B1/pl not_active IP Right Cessation
- 1996-11-18 DK DK96308318T patent/DK0776895T3/da active
- 1996-11-18 EP EP96308318A patent/EP0776895B1/en not_active Expired - Lifetime
- 1996-11-18 YU YU60996A patent/YU49315B/sh unknown
- 1996-11-19 MY MYPI96004799A patent/MY118068A/en unknown
- 1996-11-19 EG EG102296A patent/EG23871A/xx active
- 1996-11-19 CO CO96060835A patent/CO4750823A1/es unknown
- 1996-11-20 AR ARP960105254A patent/AR004336A1/es not_active Application Discontinuation
- 1996-11-20 AR ARP960105255A patent/AR004717A1/es not_active Application Discontinuation
1997
- 1997-11-07 US US08/966,081 patent/US6015807A/en not_active Expired - Lifetime
1998
- 1998-05-13 NO NO19982182A patent/NO310196B1/no not_active IP Right Cessation
- 1998-05-13 MX MX9803792A patent/MX9803792A/es unknown
- 1998-11-19 CY CY9800046A patent/CY2103B1/xx unknown
1999
- 1999-12-07 US US09/455,697 patent/US6117861A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
WO1997018809A1 (en)	1997-05-29
BR9611724A (pt)	1999-06-01
CO4750823A1 (es)	1999-03-31
EA199800374A1 (ru)	1998-10-29
US6117861A (en)	2000-09-12
NO982182L (no)	1998-05-13
SI0776895T1 (en)	1999-04-30
ES2122764T3 (es)	1998-12-16
CN1202825A (zh)	1998-12-23
PL326754A1 (en)	1998-10-26
AU711125B2 (en)	1999-10-07
KR19990067596A (ko)	1999-08-25
YU60996A (sh)	1999-03-04
ATE172199T1 (de)	1998-10-15
US5710145A (en)	1998-01-20
CZ150298A3 (cs)	1998-12-16
HUP9903377A2 (hu)	2000-02-28
AR004336A1 (es)	1998-11-04
TW403754B (en)	2000-09-01
JP3348859B2 (ja)	2002-11-20
EP0776895B1 (en)	1998-10-14
EG23871A (en)	2007-11-27
IL124417A (en)	2002-11-10
CA2237221A1 (en)	1997-05-29
CA2237221C (en)	2003-03-25
JPH11500149A (ja)	1999-01-06
DE69600784T2 (de)	1999-04-08
EP0776895A1 (en)	1997-06-04
HUP9903377A3 (en)	2000-04-28
HU226821B1 (en)	2009-11-30
CY2103B1 (en)	2002-04-05
PE22798A1 (es)	1998-05-11
MX9803792A (es)	1998-09-30
DE69600784D1 (de)	1998-11-19
RO120074B1 (ro)	2005-08-30
AR004717A1 (es)	1999-03-10
MY118068A (en)	2004-08-30
NO982182D0 (no)	1998-05-13
YU49315B (sh)	2005-06-10
IL124417A0 (en)	1998-12-06
CN1093759C (zh)	2002-11-06
DK0776895T3 (da)	1999-06-23
NZ323571A (en)	1998-12-23
AU1054897A (en)	1997-06-11
US6015807A (en)	2000-01-18
TR199800759T2 (xx)	2001-01-22
KR100304210B1 (ko)	2001-11-05
UA61897C2 (en)	2003-12-15
EA000967B1 (ru)	2000-08-28
PL184715B1 (pl)	2002-12-31
ZA969646B (en)	1998-05-18
CZ297524B6 (cs)	2007-01-03

Publication	Publication Date	Title
NO310196B1 (no)	2001-06-05	Proteinkinase C-inhibitor, anvendelse av samme for fremstilling av medikament, farmasöytisk formulering omfattendesamme, fremgangsmåte for fremstilling av samme, samt forbindelsefor bruk som terapeutikum
EP3580224B1 (en)	2022-07-13	Ask1 inhibiting agents
CN114981257B (zh)	2024-07-05	取代的吡唑并哌啶羧酸
KR20210034082A (ko)	2021-03-29	2,6-디아미노 피리딘 화합물
EP3044225B1 (en)	2024-12-18	Tricyclic gyrase inhibitors
AU701659B2 (en)	1999-02-04	Novel intermediates and their use to prepare n,n'-bridged bisindolylmaleimides
US20220153746A1 (en)	2022-05-19	Nitrogen oxide-donating pde-5 and/or pde-6 inhibitor compounds, and uses thereof
EP4324835A1 (en)	2024-02-21	Pyrimidinone derivative and preparation method therefor, pharmaceutical composition, and use
US12378260B2 (en)	2025-08-05	Benzotriazole compound
JP2023518299A (ja)	2023-04-28	小分子エナンチオマーによるアンドロゲン受容体調節
US11987575B2 (en)	2024-05-21	Tricyclic compounds as BCR-ABL inhibitors
US5721272A (en)	1998-02-24	Intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
CN113004283B (zh)	2022-08-12	作为血浆激肽释放酶抑制剂的四环类化合物及其用途
US20250296939A1 (en)	2025-09-25	Benzothiophene compound

Legal Events

Date	Code	Title	Description
2013-06-24	MM1K	Lapsed by not paying the annual fees